1Gross PL,,Weitz JI.New anticoagulants for treatment of venous thromboembolism[].Arteriosclerosis and Thrombosis.2008
2Perzborn E,Roehrig S,Straub A,et al.Rivoraxaban:a new oral factor Xa inhibitor[].Arteriosclerosis and Thrombosis.2010
3Weinz C,Schwarz T,Kubitza D,et al.Metabolism and excretion of rivaroxaban,an oral,direct Factor Xαinhibitor,in rats,dogs and humans[].Drug Metabolism and Disposition.2009
4Kakkar AK,Brenner B,Dahl OE,et al.Extended duration rivaroxa-ban versus short-term enoxaparin for the prevention of venous throm-boembolism enoxaparin for the prevention of venous thromboembolism controlled trial[].The Lancet.2008
5Turpie AG,Lassen MR,Davidson BL,et al.Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty:a randomised trial[].The Lancet.2009
6Tapson VF.Acute pulmonary embolism[].The New England Journal of Medicine.2008
7D Kubitza,M Becka,W Mueck,M Zuehlsdorf.Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban—an oral, direct Factor Xa inhibitor—are not affected by aspirin[].Journal of Clinical Pharmacology.2006
9J Choay,M Petitou,JC Lormeau.Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity[].Biochemical and Biophysical Research Communications.1983
10Laux, V,E Perzborn,D. Kubitza, et al.Preclinical and clinical characteristics of rivaroxaban:a novel,oral,direct factor Xa inhibitor[].Seminars in Thrombosis and Hemostasis.2007
